GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma ...

GSK is opening the door to a new era in urinary ... plus a new launch for biologic depemokimab. All five should help the company achieve its recently increased 2031 sales goal of more than 40 ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma and ...

GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...

GSK) is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK ranks 1st on our list of most undervalued healthcare stocks to ...

In other recent news, GSK plc announced that the US Food and Drug Administration has accepted the Biologics License Application for depemokimab, targeting asthma and chronic rhinosinusitis with nasal ...